| UniProt ID | CATD_HUMAN | |
|---|---|---|
| UniProt AC | P07339 | |
| Protein Name | Cathepsin D | |
| Gene Name | CTSD | |
| Organism | Homo sapiens (Human). | |
| Sequence Length | 412 | |
| Subcellular Localization | Lysosome. Melanosome. Secreted, extracellular space. Identified by mass spectrometry in melanosome fractions from stage I to stage IV. In aortic samples, detected as an extracellular protein loosely bound to the matrix (PubMed:20551380). | |
| Protein Description | Acid protease active in intracellular protein breakdown. Plays a role in APP processing following cleavage and activation by ADAM30 which leads to APP degradation. [PubMed: 27333034 Involved in the pathogenesis of several diseases such as breast cancer and possibly Alzheimer disease.] | |
| Protein Sequence | MQPSSLLPLALCLLAAPASALVRIPLHKFTSIRRTMSEVGGSVEDLIAKGPVSKYSQAVPAVTEGPIPEVLKNYMDAQYYGEIGIGTPPQCFTVVFDTGSSNLWVPSIHCKLLDIACWIHHKYNSDKSSTYVKNGTSFDIHYGSGSLSGYLSQDTVSVPCQSASSASALGGVKVERQVFGEATKQPGITFIAAKFDGILGMAYPRISVNNVLPVFDNLMQQKLVDQNIFSFYLSRDPDAQPGGELMLGGTDSKYYKGSLSYLNVTRKAYWQVHLDQVEVASGLTLCKEGCEAIVDTGTSLMVGPVDEVRELQKAIGAVPLIQGEYMIPCEKVSTLPAITLKLGGKGYKLSPEDYTLKVSQAGKTLCLSGFMGMDIPPPSGPLWILGDVFIGRYYTVFDRDNNRVGFAEAARL | |
| Overview of Protein Modification Sites with Functional and Structural Information | ||
|
|
||
* ASA = Accessible Surface Area
| Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
|---|---|---|---|---|---|
| 4 | Phosphorylation | ----MQPSSLLPLAL ----CCHHHHHHHHH | 19.41 | 24043423 | |
| 5 | Phosphorylation | ---MQPSSLLPLALC ---CCHHHHHHHHHH | 40.38 | 24043423 | |
| 19 | Phosphorylation | CLLAAPASALVRIPL HHHHCCHHHHHHCCH | 22.52 | 24043423 | |
| 28 | Ubiquitination | LVRIPLHKFTSIRRT HHHCCHHHHHHHHHH | 59.00 | 21890473 | |
| 30 | Phosphorylation | RIPLHKFTSIRRTMS HCCHHHHHHHHHHHH | 28.22 | 23909892 | |
| 31 | Phosphorylation | IPLHKFTSIRRTMSE CCHHHHHHHHHHHHH | 19.75 | 29496963 | |
| 35 | Phosphorylation | KFTSIRRTMSEVGGS HHHHHHHHHHHCCCC | 18.39 | 21406692 | |
| 37 | Phosphorylation | TSIRRTMSEVGGSVE HHHHHHHHHCCCCHH | 28.63 | 21406692 | |
| 42 | Phosphorylation | TMSEVGGSVEDLIAK HHHHCCCCHHHHHHC | 19.19 | 20068231 | |
| 49 | Ubiquitination | SVEDLIAKGPVSKYS CHHHHHHCCCCHHHC | 57.67 | - | |
| 53 | Phosphorylation | LIAKGPVSKYSQAVP HHHCCCCHHHCCCCC | 29.07 | 29116813 | |
| 54 | Ubiquitination | IAKGPVSKYSQAVPA HHCCCCHHHCCCCCC | 49.51 | 21890473 | |
| 56 | Phosphorylation | KGPVSKYSQAVPAVT CCCCHHHCCCCCCCC | 18.52 | 29116813 | |
| 63 | O-linked_Glycosylation | SQAVPAVTEGPIPEV CCCCCCCCCCCCHHH | 37.01 | 55825339 | |
| 63 | Phosphorylation | SQAVPAVTEGPIPEV CCCCCCCCCCCCHHH | 37.01 | 29116813 | |
| 122 | 2-Hydroxyisobutyrylation | IACWIHHKYNSDKSS HHHHHHHHCCCCCCC | 31.78 | - | |
| 127 | 2-Hydroxyisobutyrylation | HHKYNSDKSSTYVKN HHHCCCCCCCEEEEC | 46.24 | - | |
| 127 | Ubiquitination | HHKYNSDKSSTYVKN HHHCCCCCCCEEEEC | 46.24 | - | |
| 134 | N-linked_Glycosylation | KSSTYVKNGTSFDIH CCCEEEECCEEEEEE | 49.26 | 8393577 | |
| 134 | N-linked_Glycosylation | KSSTYVKNGTSFDIH CCCEEEECCEEEEEE | 49.26 | 8393577 | |
| 165 | O-linked_Glycosylation | VPCQSASSASALGGV CCCCCCCCCHHHCCC | 26.42 | OGP | |
| 184 | Ubiquitination | QVFGEATKQPGITFI EECCCCCCCCCEEEE | 62.64 | 21890473 | |
| 203 | Phosphorylation | DGILGMAYPRISVNN CCCCCCCCCEEECCC | 5.55 | 25599653 | |
| 219 | Sulfoxidation | LPVFDNLMQQKLVDQ HHHHHHHHHHHCCCC | 5.07 | 28465586 | |
| 230 | Phosphorylation | LVDQNIFSFYLSRDP CCCCCCHHEECCCCC | 14.80 | 25867546 | |
| 232 | Phosphorylation | DQNIFSFYLSRDPDA CCCCHHEECCCCCCC | 11.54 | 25867546 | |
| 234 | Phosphorylation | NIFSFYLSRDPDAQP CCHHEECCCCCCCCC | 24.21 | 25867546 | |
| 246 | Sulfoxidation | AQPGGELMLGGTDSK CCCCCEEECCCCCCC | 2.58 | 28465586 | |
| 250 | Phosphorylation | GELMLGGTDSKYYKG CEEECCCCCCCCCCC | 34.99 | 23911959 | |
| 252 | Phosphorylation | LMLGGTDSKYYKGSL EECCCCCCCCCCCCE | 23.54 | 23911959 | |
| 253 | 2-Hydroxyisobutyrylation | MLGGTDSKYYKGSLS ECCCCCCCCCCCCEE | 56.24 | - | |
| 253 | Ubiquitination | MLGGTDSKYYKGSLS ECCCCCCCCCCCCEE | 56.24 | 21890473 | |
| 254 | Phosphorylation | LGGTDSKYYKGSLSY CCCCCCCCCCCCEEE | 17.86 | 25219547 | |
| 255 | Phosphorylation | GGTDSKYYKGSLSYL CCCCCCCCCCCEEEE | 16.77 | 25219547 | |
| 258 | Phosphorylation | DSKYYKGSLSYLNVT CCCCCCCCEEEEEEC | 15.25 | 25219547 | |
| 260 | Phosphorylation | KYYKGSLSYLNVTRK CCCCCCEEEEEECCC | 29.31 | 28060719 | |
| 261 | Phosphorylation | YYKGSLSYLNVTRKA CCCCCEEEEEECCCE | 13.95 | 28060719 | |
| 263 | N-linked_Glycosylation | KGSLSYLNVTRKAYW CCCEEEEEECCCEEE | 25.53 | 8393577 | |
| 263 | N-linked_Glycosylation | KGSLSYLNVTRKAYW CCCEEEEEECCCEEE | 25.53 | 8393577 | |
| 265 | Phosphorylation | SLSYLNVTRKAYWQV CEEEEEECCCEEEEE | 25.94 | 28060719 | |
| 269 | Phosphorylation | LNVTRKAYWQVHLDQ EEECCCEEEEEEHHH | 10.21 | 25219547 | |
| 301 | Sulfoxidation | VDTGTSLMVGPVDEV EECCCCEEEECHHHH | 3.07 | 30846556 | |
| 313 | Ubiquitination | DEVRELQKAIGAVPL HHHHHHHHHHCCCCE | 55.38 | - | |
| 325 | Phosphorylation | VPLIQGEYMIPCEKV CCEECCEEEEECCCC | 13.73 | - | |
| 326 | Sulfoxidation | PLIQGEYMIPCEKVS CEECCEEEEECCCCC | 2.10 | 28465586 | |
| 329 | Glutathionylation | QGEYMIPCEKVSTLP CCEEEEECCCCCCCC | 5.67 | 22555962 | |
| 331 | Ubiquitination | EYMIPCEKVSTLPAI EEEEECCCCCCCCEE | 48.48 | - | |
| 333 | Phosphorylation | MIPCEKVSTLPAITL EEECCCCCCCCEEEE | 34.98 | 23911959 | |
| 334 | Phosphorylation | IPCEKVSTLPAITLK EECCCCCCCCEEEEE | 39.48 | 23911959 | |
| 339 | Phosphorylation | VSTLPAITLKLGGKG CCCCCEEEEEECCCC | 21.68 | 20071362 | |
| 341 | Ubiquitination | TLPAITLKLGGKGYK CCCEEEEEECCCCEE | 36.11 | - | |
| 341 | Malonylation | TLPAITLKLGGKGYK CCCEEEEEECCCCEE | 36.11 | 30639696 | |
| 347 | Phosphorylation | LKLGGKGYKLSPEDY EEECCCCEECCHHHE | 16.55 | - | |
| 348 | Ubiquitination | KLGGKGYKLSPEDYT EECCCCEECCHHHEE | 51.67 | 21890473 | |
| 354 | Phosphorylation | YKLSPEDYTLKVSQA EECCHHHEEEEEECC | 16.59 | - | |
| 357 | Ubiquitination | SPEDYTLKVSQAGKT CHHHEEEEEECCCCE | 31.85 | - | |
| 359 | Phosphorylation | EDYTLKVSQAGKTLC HHEEEEEECCCCEEE | 16.84 | 24247654 | |
| 394 | Phosphorylation | DVFIGRYYTVFDRDN CEEEECEEEEEECCC | 8.62 | - |
| Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
|---|---|---|---|---|---|---|
Oops, there are no upstream regulatory protein records of CATD_HUMAN !! | ||||||
| Modified Location | Modified Residue | Modification | Function | Reference | ||
|---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of CATD_HUMAN !! | ||||||
* Distance = the distance between SAP position and PTM sites.
| Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
|---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of CATD_HUMAN !! | ||||||
| Interacting Protein | Gene Name | Interaction Type | PPI Reference | Domain-Domain Interactions |
|---|---|---|---|---|
| PPGB_HUMAN | CTSA | physical | 22939629 | |
| ACADM_HUMAN | ACADM | physical | 26344197 | |
| ETFA_HUMAN | ETFA | physical | 26344197 | |
| GRHPR_HUMAN | GRHPR | physical | 26344197 | |
| ENPL_HUMAN | HSP90B1 | physical | 26344197 | |
| PCBP1_HUMAN | PCBP1 | physical | 26344197 | |
| RAB5A_HUMAN | RAB5A | physical | 26344197 | |
| SCNNG_HUMAN | SCNN1G | physical | 26344197 | |
| SCYL2_HUMAN | SCYL2 | physical | 26344197 | |
| QCR2_HUMAN | UQCRC2 | physical | 26344197 | |
| SYUA_HUMAN | SNCA | physical | 25617759 |
| Kegg Disease | ||||||
|---|---|---|---|---|---|---|
| There are no disease associations of PTM sites. | ||||||
| OMIM Disease | ||||||
| 610127 | Ceroid lipofuscinosis, neuronal, 10 (CLN10) | |||||
| Kegg Drug | ||||||
| There are no disease associations of PTM sites. | ||||||
| DrugBank | ||||||
| There are no disease associations of PTM sites. | ||||||
loading...
| N-linked Glycosylation | |
| Reference | PubMed |
| "Crystal structures of native and inhibited forms of human cathepsinD: implications for lysosomal targeting and drug design."; Baldwin E.T., Bhat T.N., Gulnik S., Hosur M.V., Sowder R.C. II,Cachau R.E., Collins J., Silva A.M., Erickson J.W.; Proc. Natl. Acad. Sci. U.S.A. 90:6796-6800(1993). Cited for: X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS). | |
| "Glycoproteomics analysis of human liver tissue by combination ofmultiple enzyme digestion and hydrazide chemistry."; Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.; J. Proteome Res. 8:651-661(2009). Cited for: GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-134 AND ASN-263, AND MASSSPECTROMETRY. | |
| "Elucidation of N-glycosylation sites on human platelet proteins: aglycoproteomic approach."; Lewandrowski U., Moebius J., Walter U., Sickmann A.; Mol. Cell. Proteomics 5:226-233(2006). Cited for: GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-263, AND MASSSPECTROMETRY. | |
| "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,hydrazide chemistry, and mass spectrometry."; Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,Moore R.J., Smith R.D.; J. Proteome Res. 4:2070-2080(2005). Cited for: GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-263, AND MASSSPECTROMETRY. | |
| "Identification and quantification of N-linked glycoproteins usinghydrazide chemistry, stable isotope labeling and mass spectrometry."; Zhang H., Li X.-J., Martin D.B., Aebersold R.; Nat. Biotechnol. 21:660-666(2003). Cited for: GLYCOSYLATION AT ASN-263. | |